Ann: Zantrene data published in Cancer Research Journal, page-15

I’m a bowel cancer surgeon. 5-FU is the cornerstone systemic treatment for bowel cancer, so anything that improves sensitivity could be a big deal. There are so many research avenues to pursue, and it’s ubiquity in various cancer types indicates that we are really only the tip of the iceberg as to its potential. Once FTO gains some scientific traction, I would expect a flurry of medical and investment interest.

I’m happy to have been buying again at these levels, and I’m predicting that 1.50 is well and truly within the company buying range as a support.